EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 852 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the WHO Global Status Report on Cancer with Key Recommendations for Equitable Cancer Care Lorlatinib Continues to Show Long-Term Benefit in Newly-Diagnosed Patients with Advanced ALK-positive NSCLC GLP-1 Receptor Agonist Use Associated with a Significantly Lower Short-Term Incidence of Obesity-Associated Cancers Among Obese Individuals Without Diabetes MOST POPULAR Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... May 1, 2021 Cancer in My Community: Overcoming Delays in Care for Children With... July 6, 2023 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung... April 25, 2024 Load more HOT NEWS Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast... Prevalence of ALK Alterations in Non-Small Cell Lung Cancer Determined At 27, She Was Told She Was Too Young For Breast... Merging the Histologic and Molecular Data Into an Integrated Score Significantly...
